Bioventix PLC (AIM:BVXP)

Market Cap	86.47M -41.9%
Revenue (ttm)	12.54M -8.2%
Net Income	7.44M -5.2%
EPS	1.41 -5.1%
Shares Out	5.22M
PE Ratio	11.78
Forward PE	n/a
Dividend	1.50 (9.23%)
Ex-Dividend Date	Apr 9, 2026

Volume	383
Open	1,650.00
Previous Close	1,655.00
Day's Range	1,600.00 - 1,700.00
52-Week Range	1,300.00 - 3,020.00
Beta	0.55
Analysts	n/a
Price Target	3,900.00 (+132.14%)
Earnings Date	Jun 26, 2026

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 12
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error